| Who is it? | Microbiologist |
| Birth Day | August 23, 1931 |
| Birth Place | New York City, New York, United States |
| Age | 92 YEARS OLD |
| Birth Sign | Virgo |
| Alma mater | University of California, Berkeley, BA Johns Hopkins School of Medicine, MD |
| Known for | restriction enzymes |
Hamilton O. Smith, a renowned microbiologist in the United States, is projected to have a net worth ranging from $100K to $1M by the year 2024. With his exceptional contributions to the field of microbiology, Smith has established a reputable career focused on unlocking the secrets of microorganisms. As a distinguished figure in his field, his net worth reflects the recognition he has received for his groundbreaking research and the impact it has had on the scientific community. Hamilton O. Smith's dedication and expertise have solidified his position as a key contributor to advancements in microbiology.
Smith was born on August 23, 1931, and graduated from University Laboratory High School of Urbana, Illinois. He attended the University of Illinois at Urbana-Champaign, but in 1950 transferred to the University of California, Berkeley, where he earned his B.A. in Mathematics in 1952 [1]. He received his medical degree from Johns Hopkins University in 1956. In 1975, he was awarded a Guggenheim Fellowship he spent at the University of Zurich.
In 1970, Smith and Kent W. Wilcox discovered the first type II restriction enzyme, that is now called as HindII. Smith went on to discover DNA methylases that constitute the other half of the bacterial host restriction and modification systems, as hypothesized by Werner Arber of Switzerland.
He was awarded the Nobel Prize in Physiology or Medicine in 1978 for discovering type II restriction enzymes with Werner Arber and Daniel Nathans as co-recipients.
He later became a leading figure in the nascent field of genomics, when in 1995 he and a team at The Institute for Genomic Research sequenced the first bacterial genome, that of Haemophilus influenzae. H. influenza was the same organism in which Smith had discovered restriction enzymes in the late 1960s. He subsequently played a key role in the sequencing of many of the early genomes at The Institute for Genomic Research, and in the assembly of the human genome at Celera Genomics, which he joined when it was founded in 1998.
More recently, he has directed a team at the J. Craig Venter Institute that works towards creating a partially synthetic bacterium, Mycoplasma laboratorium. In 2003 the same group synthetically assembled the genome of a virus, Phi X 174 bacteriophage. Currently, Smith is scientific Director of privately held Synthetic Genomics, which was founded in 2005 by Craig Venter to continue this work. Currently, Synthetic Genomics is working to produce biofuels on an industrial-scale using recombinant algae and other microorganisms.
